In: Press Release

HORSHAM, PA. — Ancillare, LP has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries. As Ancillare expands its global footprint into Europe, Middle East, and Africa (EMEA) – their European depot had to be equipped to meet the global needs of our clients. Cathy Porretti, Executive Vice President of Global Operations and Information Technology, who is responsible for the daily management for its Master Depot in Milton Keynes, United Kingdom, has been working diligently on the global distribution strategies of clinical and ancillary supplies.

In early February, Ancillare announced the appointment of Executive Vice President, Global Clinical Development, Gurinder Shinmar, whose focus will be driving the global expansion in EMEA and APAC regions with the Ancillare Turn-Key Operation (A-TKO™) model as a solution for study sponsors and CROs with complex, global clinical trials. As new opportunities are brought to fruition by the Global Clinical Development team, Porretti’s team will be prepared to execute.

“Cathy has been key to the ongoing success of our United Kingdom depot and with Brexit on the horizon, Ancillare is making every effort to prepare for the unknown,” said Joanne Santomauro, Ancillare’s Chief Executive Officer “We believe her ongoing oversight of our United Kingdom daily operations will allow us to maximize Gurinder’s time and energy in service to both current, and prospective, sponsor and CRO Executive Leadership teams.”

According to Santomauro, both roles, will allow for our clients to realize a more seamless transition from onboarding and protocol design to execution and day-to-day support. Porretti, who has served in a Global Operations Executive Leadership capacity for nearly 30 years, and has been instrumental to Ancillare’s rapid growth since its inception in 2006.

About Ancillare, LP

Ancillare is the only organization of its kind with an exclusive focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s Turn-Key Operations (A-TKO™) model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improving operational efficiency across all levels of the value chain.

Ancillare has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Approaching Brexit deadline, new licensure will enable continuous global clinical trial operations for sponsors and CROs

HORSHAM, PA. — January 31, 2018. Global Clinical and Ancillary Supply Chain leader Ancillare, LP, the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations, today announced it has been awarded a Wholesale Distribution Authorization (WDA) for Human use by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA).

The award, which comes in response to the United Kingdom’s anticipated departure from the E.U.—commonly called “Brexit”—will allow Ancillare to continue to support study sponsors’ European needs, even while Brexit’s impact on pharmaceutical supply chains remains unclear. The licensure is a critical victory for the dozens of study sponsors, CROs and MROs for whom the U.K. market is a vital link in complex, global clinical trial portfolios and supply chains.

“I think [the license is] a testament to the integrity and dedication of our global team,” said Joanne Santomauro, CEO, Ancillare. “No matter how rapidly or exponentially things have changed on the global stage, we’ll always be ready to respond in service to our sponsors.”

Ancillare received the license following an intensive evaluation, auditing and inspections process. Among the qualifying criteria for the license was that Ancillare was in full compliance with the 2012 Human Medicines Regulations, and with the requirements of Good Distribution Practice (GDP). Ancillare’s WDA will enable ongoing wholesaling and distribution activities—including procurement, holding, supply and export—from its European regional office and master depot in Milton Keynes.

“I’m proud that Ancillare has emerged even better equipped to meet the clinical and ancillary supply chain needs of study sponsors,” Santomauro added.

In response to its confirmed regulatory compliance status, as well as ongoing Brexit requirements, Ancillare anticipates adding staff at its United Kingdom office, in order to drive global expansion efforts throughout Europe, the Middle East, Africa and Asia-Pacific. Ancillare expects to announce the staff changes later in Q1 2018.

 

About Ancillare, LP

Ancillare is the only organization of its kind with an exclusive focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s Turn-Key Operations (A-TKO™) model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improving operational efficiency across all levels of the value chain.

Ancillare has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine. To learn more, visit ancillare.com.

HORSHAM, PA. — Global Clinical and Ancillary Supply Chain leader Ancillare, LP—the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations—today announced that David J. DelCollo, Esq., its primary in-house counsel, has been awarded both “Top 100 Lawyer” and “Top 40 Under 40” recognitions.

The recognitions come on the heels of DelCollo’s first year as Ancillare’s general counsel. Prior to joining Ancillare, he served as Senior Counsel for Bioclinica, where he worked to develop and protect the company’s intellectual property and licensing rights. DelCollo brought more than a decade of legal experience in practice areas such as corporate, contract and healthcare law to Ancillare—knowledge which he made quick use of, according to Ancillare leadership.

“David has made tremendous contributions this year and I think these awards are apropos,” said Joanne Santomauro, CEO at Ancillare. “He’s a skilled attorney. Not only as he helped [Ancillare] define our legal policies, he’s put us on a path to a more secure future.”

Prior to his success in corporate law, DelCollo represented the Commonwealth in the courtroom. As an Assistant District Attorney in the Greater Philadelphia Area, he personally prosecuted over 1,000 cases, winning favorable verdicts and outcomes 97% of the time.

DelCollo holds a J.D. from Widener University School of Law, where he was a member of the Trial Advocacy team.

The recognition of “Top 100 Lawyer” was awarded by executive profile publication International Top 100 Magazine. DelCollo’s “Top 40 Under 40” spotlight will be featured a forthcoming 2018 edition of the same magazine.

About Ancillare, LP

Ancillare is the only organization of its kind with a singular focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s A-TKO™ model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improves operational efficiency across all levels of the value chain.

Ancillare has experience in working over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine.

 

HORSHAM, PA. – Ancillare, LP, the leader in end-to-end global clinical trial ancillary supply chain management services for pharmaceutical, biotechnology, contract research and medical research organizations, announced today the appointment of Nitin Jain to a new position as Vice President of the Asia-Pacific (APAC) region.
Nitin will focus on driving operational excellence to support our client’s clinical supply chain needs and oversee the complete end-to-end supply chain management operations of Ancillare’s Singapore Master Depot. Nitin brings to Ancillare over 18 years of business development, general management, strategic alliances, supply chain management and operations experience in pharmaceutical, biotechnology and contract research organizations around the world. Nitin has held senior positions at INC Research, Covance, Theorem Clinical Research and Worldwide Clinical Trials.
“We see significant growth potential in the APAC region. Nitin’s extensive experience and strong drive makes him a great fit to lead our operations and growth in the APAC region,” said Joanne Santomauro, Chief Executive Officer at Ancillare. “By expanding our operations in Asia-Pacific this strengthens our ability to provide our clients with a single source for all their clinical trial supply chain needs.”

Singapore along with our strategic depots in China and Korea will provide Ancillare with the gateway to the entire APAC region by incorporating standard processes and procedures under one quality driven operation. The Singapore Operation will augment Ancillare’s strategic and master depot network so that our sponsors’ clinical operations leaders will have one point of expert contact and one clinical supply chain to manage all global trials needs from pre-protocol launch and first patient/first visit through last patient/last visit, site closeout and reclamation.

About Ancillare, LP
Ancillare, LP has extensive experience delivering cost savings and efficiencies to supply chains, with a complete turn-key approach for managing the pharmaceutical, biotechnology, contract research and medical research organizations’ clinical trial supply chains with a singular focus. Our turn-key global model (A-TKOTM) centralizes supply operations which accelerates the processes, lowers costs and mitigates risk by making clinical supply chains more efficient, cost-effective and global.

Our capabilities include pre-protocol analysis and planning, contribution to overall program feasibility assessments and timeline development, product sourcing and procurement, forecasting and budgeting, large and small equipment and consumables management, patient retention and recruitment materials, customs clearance, import/export (including IOR/EOR), storage, kitting, distribution and returns management/disposition (including destruction, refurbishment/recalibration and redeployment) on a global level.

Ancillare has master depots in United States, United Kingdom and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan and Ukraine. To learn more, visit ancillare.com or contact us via LinkedIn, Twitter and Facebook.

HORSHAM, PA.–Ancillare, LP’s Joanne Santomauro, Chief Executive Officer and Founder, is being recognized by Marcum LLP and Philadelphia SmartCEO as a finalist for their 2016 Marcum Innovator of the Year award.

The Marcum Innovator of the Year award honors business leaders who have developed products and services that improve the quality of life and business practice in Philadelphia. Finalists are pioneering new advancements in the biotechnology, healthcare, business services, manufacturing, real estate and technology industries. The winners will be announced on October 26, 2016 at the Sugarhouse Casino in Philadelphia, PA.

“I am honored to be recognized as a Marcum Innovator of the Year finalist. This recognition shows the dedication, support, commitment and excellence of the entire organization.” said Joanne Santomauro.

With Joanne’s forward thinking, she was able to create the ancillary supply chain management industry. Prior to the company’s launch in 2006, pharmaceutical, biotechnology and medical research organizations had little transparency and a lack of understanding of the associated costs, processes, regulatory and compliance requirements of the clinical supply chain. Over the last decade Joanne took the company to explosive growth around the world through dedication, innovative solutions including the Ancillare Turn Key Operative Model (A-TKO) and cutting-edge processes.

About Ancillare, LP
Ancillare, LP has extensive experience delivering cost savings and efficiencies to supply chains, with a complete turn-key approach for managing the pharmaceutical, biotechnology, contract research and medical research organizations’ clinical trial supply chains with a singular focus. Our turn-key global model (A-TKO) centralizes supply operations which accelerates the processes, lowers costs and mitigates risk by making clinical supply chains more efficient, cost-effective and global.
Our capabilities include pre-protocol analysis and planning, contribution to overall program feasibility assessments and timeline development, product sourcing and procurement, forecasting and budgeting, large and small equipment and consumables management, patient retention and recruitment materials, customs clearance, import/export (including IOR/EOR), storage, kitting, distribution and returns management/disposition (including destruction, refurbishment/recalibration and redeployment) on a global level.

Ancillare has managed the supply chain for top pharmaceutical and CRO organizations and has successfully transported goods to 100 countries. Ancillare has master depots in United States, United Kingdom and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan and Ukraine. To learn more, visit www.ancillare.com or contact us via LinkedIn, Twitter and Facebook.